Envarsus Versus Advagraf in De Novo Kidney Transplant Recipients: A Comparative Pharmacokinetic Study
In de novo kidney transplant recipients, Envarsus provides higher early tacrolimus exposure and consistently higher dose-normalized trough exposure than Advagraf, enabling lower maintenance doses while maintaining similar short-term effectiveness and safety. However, early overexposure was more frequent with Envarsus at 0.15 mg/kg/day, supporting careful early monitoring and consideration of lower starting doses.
Authors
- P Mas-Serrano
- Noelia Balibrea
- R Nalda-Molina
- A Ramon-Lopez
- Antonio Franco
- Isabel Gascón-Ros
- Moreno Díaz
- Elena De la Cruz
- Javier Perez-Contreras
Institutions
- Universitat de Miguel Hernández d'Elx (ES)
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES)
Publication Details
- Journal
- Life
- Published
- 2026-02-02
- DOI
- https://doi.org/10.3390/life16020256
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00